查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1862283

胰岛素原料药（API）－全球市场份额和排名、总收入和需求预测（2025-2031年）

Insulin API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024年全球胰岛素原料药市场规模预计为28.49亿美元，预计到2031年将达到37.61亿美元，2025年至2031年的复合年增长率为4.1%。

本报告对近期关税调整和国际策略反制措施对跨境原料药产业基础、资本配置模式、区域经济相互依存关係和供应链重组的影响进行了全面评估。

胰岛素原料药）是指用于生产胰岛素类药物的主要生物活性物质。它利用重组DNA技术，透过基因改造微生物（例如大肠桿菌和酵母）生产。胰岛素原料药可配製成多种胰岛素製剂，包括速效、中效和长效胰岛素类似物，在糖尿病管理中扮演至关重要的角色。预计到2024年，全球胰岛素原料药产量将达到约558,300吨，全球平均市场价格约为每克51美元。

胰岛素用于治疗第一型糖尿病（一种人体无法产生胰岛素，因而无法控制血糖值的疾病）。它也用于治疗需要胰岛素治疗的第二型糖尿病患者（一种人体无法正常利用胰岛素，因而无法控制血糖水平的疾病）。目前，胰岛素是一种重要的药物，广泛用于糖尿病的治疗。

胰岛素原料药市场成长的主要驱动力是全球糖尿病（尤其是第2型糖尿病）的日益流行，而第二型糖尿病的流行主要归因于人口老化、久坐不动的生活方式和不健康的饮食习惯。随着确诊患者数量的增加，对胰岛素治疗方法的需求持续成长，尤其是在治疗机会不断扩大的发展中地区。此外，重组DNA技术和生物相似药研发的进步使得胰岛素原料药能够以低成本、大规模的方式生产，从而促进了市场扩张和新进者的涌现。

然而，儘管市场需求强劲，胰岛素原料药市场仍面临许多挑战，包括生产流程复杂以及生物製药监管要求严格。胰岛素原料药的生产涉及先进的生物技术工艺，需要大量的资本投入、熟练的劳动力以及严格的品管，这可能会限制中小企业的进入。此外，少数主要供应商造成的市场垄断以及许多国家政府成本控制政策带来的价格压力，也阻碍了新企业的进入，并降低了生产商的利润率。

本报告旨在对全球胰岛素原料药市场按地区/国家、类型和应用进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

本报告以2024年为基准年，按销售量（吨）和收入（百万美元）对胰岛素原料药市场规模、估算和预测进行了呈现，并涵盖了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定胰岛素原料药的业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Novo Nordisk
  • Sanofi-Aventis
  • Eli Lilly
  • Tonghua Dongbao
  • Ganlee
  • United Laboratory
  • Biocon
  • Amphastar
  • Wockhardt
  • Julphar Diabetes
  • Torrent Pharma

按类型分類的细分市场

  • 常规人类胰岛素
  • 胰岛素类似物

按动作持续时间分段

  • 快速起效
  • 短效
  • 中间类型
  • 长效
  • 超长效

应用领域

  • 製药生产
  • 生物相似药研发
  • 科学研究
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Insulin API was estimated to be worth US$ 2849 million in 2024 and is forecast to a readjusted size of US$ 3761 million by 2031 with a CAGR of 4.1% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Insulin API cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Insulin API refers to the biologically active substance used as the primary component in the manufacturing of insulin-based medications. It is produced through recombinant DNA technology using genetically engineered microorganisms such as E. coli or yeast. The insulin API can be formulated into various insulin types, including short-acting, intermediate-acting, and long-acting insulin analogs, which are critical for the management of diabetes mellitus.In 2024, global Insulin API production reached approximately 55.83 mt, with an average global market price of around US$ 51 per g.

Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.

The insulin API market is primarily driven by the rising global prevalence of diabetes, particularly Type 2 diabetes, fueled by aging populations, sedentary lifestyles, and unhealthy diets. As more patients are diagnosed, the demand for insulin-based therapies continues to increase, especially in developing regions where access to treatment is expanding. Additionally, advancements in recombinant DNA technology and biosimilar development have enabled cost-effective and large-scale production of insulin APIs, supporting broader market growth and the entry of new players.

Despite strong demand, the insulin API market faces significant challenges, including high manufacturing complexity and stringent regulatory requirements for biologics. The production of insulin APIs involves advanced biotechnological processes, requiring substantial capital investment, skilled labor, and rigorous quality control, which can limit the participation of smaller companies. Moreover, market consolidation among a few major suppliers and pricing pressure from government cost-control policies in many countries pose hurdles for newer entrants and reduce profit margins for manufacturers.

This report aims to provide a comprehensive presentation of the global market for Insulin API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Insulin API by region & country, by Type, and by Application.

The Insulin API market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin API.

Market Segmentation

By Company

  • Novo Nordisk
  • Sanofi-Aventis
  • Eli Lilly
  • Tonghua Dongbao
  • Ganlee
  • United Laboratory
  • Biocon
  • Amphastar
  • Wockhardt
  • Julphar Diabetes
  • Torrent Pharma

Segment by Type

  • Regular Human Insulin
  • Insulin Analogue

Segment by Acting

  • Rapid-acting
  • Short-acting
  • Intermediate-acting
  • Long-acting
  • Ultra-long-acting

Segment by Application

  • Preparation Production
  • Biosimilar Drug Development
  • Scientific Research
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Insulin API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Insulin API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Insulin API in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Insulin API Product Introduction
  • 1.2 Global Insulin API Market Size Forecast
    • 1.2.1 Global Insulin API Sales Value (2020-2031)
    • 1.2.2 Global Insulin API Sales Volume (2020-2031)
    • 1.2.3 Global Insulin API Sales Price (2020-2031)
  • 1.3 Insulin API Market Trends & Drivers
    • 1.3.1 Insulin API Industry Trends
    • 1.3.2 Insulin API Market Drivers & Opportunity
    • 1.3.3 Insulin API Market Challenges
    • 1.3.4 Insulin API Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Insulin API Players Revenue Ranking (2024)
  • 2.2 Global Insulin API Revenue by Company (2020-2025)
  • 2.3 Global Insulin API Players Sales Volume Ranking (2024)
  • 2.4 Global Insulin API Sales Volume by Company Players (2020-2025)
  • 2.5 Global Insulin API Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Insulin API Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Insulin API Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Insulin API
  • 2.9 Insulin API Market Competitive Analysis
    • 2.9.1 Insulin API Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Insulin API Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Insulin API as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Regular Human Insulin
    • 3.1.2 Insulin Analogue
  • 3.2 Global Insulin API Sales Value by Type
    • 3.2.1 Global Insulin API Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Insulin API Sales Value, by Type (2020-2031)
    • 3.2.3 Global Insulin API Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Insulin API Sales Volume by Type
    • 3.3.1 Global Insulin API Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Insulin API Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Insulin API Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Insulin API Average Price by Type (2020-2031)

4 Segmentation by Acting

  • 4.1 Introduction by Acting
    • 4.1.1 Rapid-acting
    • 4.1.2 Short-acting
    • 4.1.3 Intermediate-acting
    • 4.1.4 Long-acting
    • 4.1.5 Ultra-long-acting
  • 4.2 Global Insulin API Sales Value by Acting
    • 4.2.1 Global Insulin API Sales Value by Acting (2020 VS 2024 VS 2031)
    • 4.2.2 Global Insulin API Sales Value, by Acting (2020-2031)
    • 4.2.3 Global Insulin API Sales Value, by Acting (%) (2020-2031)
  • 4.3 Global Insulin API Sales Volume by Acting
    • 4.3.1 Global Insulin API Sales Volume by Acting (2020 VS 2024 VS 2031)
    • 4.3.2 Global Insulin API Sales Volume, by Acting (2020-2031)
    • 4.3.3 Global Insulin API Sales Volume, by Acting (%) (2020-2031)
  • 4.4 Global Insulin API Average Price by Acting (2020-2031)

5 Segmentation by Application

  • 5.1 Introduction by Application
    • 5.1.1 Preparation Production
    • 5.1.2 Biosimilar Drug Development
    • 5.1.3 Scientific Research
    • 5.1.4 Other
  • 5.2 Global Insulin API Sales Value by Application
    • 5.2.1 Global Insulin API Sales Value by Application (2020 VS 2024 VS 2031)
    • 5.2.2 Global Insulin API Sales Value, by Application (2020-2031)
    • 5.2.3 Global Insulin API Sales Value, by Application (%) (2020-2031)
  • 5.3 Global Insulin API Sales Volume by Application
    • 5.3.1 Global Insulin API Sales Volume by Application (2020 VS 2024 VS 2031)
    • 5.3.2 Global Insulin API Sales Volume, by Application (2020-2031)
    • 5.3.3 Global Insulin API Sales Volume, by Application (%) (2020-2031)
  • 5.4 Global Insulin API Average Price by Application (2020-2031)

6 Segmentation by Region

  • 6.1 Global Insulin API Sales Value by Region
    • 6.1.1 Global Insulin API Sales Value by Region: 2020 VS 2024 VS 2031
    • 6.1.2 Global Insulin API Sales Value by Region (2020-2025)
    • 6.1.3 Global Insulin API Sales Value by Region (2026-2031)
    • 6.1.4 Global Insulin API Sales Value by Region (%), (2020-2031)
  • 6.2 Global Insulin API Sales Volume by Region
    • 6.2.1 Global Insulin API Sales Volume by Region: 2020 VS 2024 VS 2031
    • 6.2.2 Global Insulin API Sales Volume by Region (2020-2025)
    • 6.2.3 Global Insulin API Sales Volume by Region (2026-2031)
    • 6.2.4 Global Insulin API Sales Volume by Region (%), (2020-2031)
  • 6.3 Global Insulin API Average Price by Region (2020-2031)
  • 6.4 North America
    • 6.4.1 North America Insulin API Sales Value, 2020-2031
    • 6.4.2 North America Insulin API Sales Value by Country (%), 2024 VS 2031
  • 6.5 Europe
    • 6.5.1 Europe Insulin API Sales Value, 2020-2031
    • 6.5.2 Europe Insulin API Sales Value by Country (%), 2024 VS 2031
  • 6.6 Asia Pacific
    • 6.6.1 Asia Pacific Insulin API Sales Value, 2020-2031
    • 6.6.2 Asia Pacific Insulin API Sales Value by Region (%), 2024 VS 2031
  • 6.7 South America
    • 6.7.1 South America Insulin API Sales Value, 2020-2031
    • 6.7.2 South America Insulin API Sales Value by Country (%), 2024 VS 2031
  • 6.8 Middle East & Africa
    • 6.8.1 Middle East & Africa Insulin API Sales Value, 2020-2031
    • 6.8.2 Middle East & Africa Insulin API Sales Value by Country (%), 2024 VS 2031

7 Segmentation by Key Countries/Regions

  • 7.1 Key Countries/Regions Insulin API Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 7.2 Key Countries/Regions Insulin API Sales Value and Sales Volume
    • 7.2.1 Key Countries/Regions Insulin API Sales Value, 2020-2031
    • 7.2.2 Key Countries/Regions Insulin API Sales Volume, 2020-2031
  • 7.3 United States
    • 7.3.1 United States Insulin API Sales Value, 2020-2031
    • 7.3.2 United States Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.3.3 United States Insulin API Sales Value by Application, 2024 VS 2031
  • 7.4 Europe
    • 7.4.1 Europe Insulin API Sales Value, 2020-2031
    • 7.4.2 Europe Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.4.3 Europe Insulin API Sales Value by Application, 2024 VS 2031
  • 7.5 China
    • 7.5.1 China Insulin API Sales Value, 2020-2031
    • 7.5.2 China Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.5.3 China Insulin API Sales Value by Application, 2024 VS 2031
  • 7.6 Japan
    • 7.6.1 Japan Insulin API Sales Value, 2020-2031
    • 7.6.2 Japan Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.6.3 Japan Insulin API Sales Value by Application, 2024 VS 2031
  • 7.7 South Korea
    • 7.7.1 South Korea Insulin API Sales Value, 2020-2031
    • 7.7.2 South Korea Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.7.3 South Korea Insulin API Sales Value by Application, 2024 VS 2031
  • 7.8 Southeast Asia
    • 7.8.1 Southeast Asia Insulin API Sales Value, 2020-2031
    • 7.8.2 Southeast Asia Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.8.3 Southeast Asia Insulin API Sales Value by Application, 2024 VS 2031
  • 7.9 India
    • 7.9.1 India Insulin API Sales Value, 2020-2031
    • 7.9.2 India Insulin API Sales Value by Type (%), 2024 VS 2031
    • 7.9.3 India Insulin API Sales Value by Application, 2024 VS 2031

8 Company Profiles

  • 8.1 Novo Nordisk
    • 8.1.1 Novo Nordisk Company Information
    • 8.1.2 Novo Nordisk Introduction and Business Overview
    • 8.1.3 Novo Nordisk Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.1.4 Novo Nordisk Insulin API Product Offerings
    • 8.1.5 Novo Nordisk Recent Development
  • 8.2 Sanofi-Aventis
    • 8.2.1 Sanofi-Aventis Company Information
    • 8.2.2 Sanofi-Aventis Introduction and Business Overview
    • 8.2.3 Sanofi-Aventis Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.2.4 Sanofi-Aventis Insulin API Product Offerings
    • 8.2.5 Sanofi-Aventis Recent Development
  • 8.3 Eli Lilly
    • 8.3.1 Eli Lilly Company Information
    • 8.3.2 Eli Lilly Introduction and Business Overview
    • 8.3.3 Eli Lilly Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.3.4 Eli Lilly Insulin API Product Offerings
    • 8.3.5 Eli Lilly Recent Development
  • 8.4 Tonghua Dongbao
    • 8.4.1 Tonghua Dongbao Company Information
    • 8.4.2 Tonghua Dongbao Introduction and Business Overview
    • 8.4.3 Tonghua Dongbao Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.4.4 Tonghua Dongbao Insulin API Product Offerings
    • 8.4.5 Tonghua Dongbao Recent Development
  • 8.5 Ganlee
    • 8.5.1 Ganlee Company Information
    • 8.5.2 Ganlee Introduction and Business Overview
    • 8.5.3 Ganlee Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.5.4 Ganlee Insulin API Product Offerings
    • 8.5.5 Ganlee Recent Development
  • 8.6 United Laboratory
    • 8.6.1 United Laboratory Company Information
    • 8.6.2 United Laboratory Introduction and Business Overview
    • 8.6.3 United Laboratory Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.6.4 United Laboratory Insulin API Product Offerings
    • 8.6.5 United Laboratory Recent Development
  • 8.7 Biocon
    • 8.7.1 Biocon Company Information
    • 8.7.2 Biocon Introduction and Business Overview
    • 8.7.3 Biocon Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.7.4 Biocon Insulin API Product Offerings
    • 8.7.5 Biocon Recent Development
  • 8.8 Amphastar
    • 8.8.1 Amphastar Company Information
    • 8.8.2 Amphastar Introduction and Business Overview
    • 8.8.3 Amphastar Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.8.4 Amphastar Insulin API Product Offerings
    • 8.8.5 Amphastar Recent Development
  • 8.9 Wockhardt
    • 8.9.1 Wockhardt Company Information
    • 8.9.2 Wockhardt Introduction and Business Overview
    • 8.9.3 Wockhardt Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.9.4 Wockhardt Insulin API Product Offerings
    • 8.9.5 Wockhardt Recent Development
  • 8.10 Julphar Diabetes
    • 8.10.1 Julphar Diabetes Company Information
    • 8.10.2 Julphar Diabetes Introduction and Business Overview
    • 8.10.3 Julphar Diabetes Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.10.4 Julphar Diabetes Insulin API Product Offerings
    • 8.10.5 Julphar Diabetes Recent Development
  • 8.11 Torrent Pharma
    • 8.11.1 Torrent Pharma Company Information
    • 8.11.2 Torrent Pharma Introduction and Business Overview
    • 8.11.3 Torrent Pharma Insulin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 8.11.4 Torrent Pharma Insulin API Product Offerings
    • 8.11.5 Torrent Pharma Recent Development

9 Industry Chain Analysis

  • 9.1 Insulin API Industrial Chain
  • 9.2 Insulin API Upstream Analysis
    • 9.2.1 Key Raw Materials
    • 9.2.2 Raw Materials Key Suppliers
    • 9.2.3 Manufacturing Cost Structure
  • 9.3 Midstream Analysis
  • 9.4 Downstream Analysis (Customers Analysis)
  • 9.5 Sales Model and Sales Channels
    • 9.5.1 Insulin API Sales Model
    • 9.5.2 Sales Channel
    • 9.5.3 Insulin API Distributors

10 Research Findings and Conclusion

11 Appendix

  • 11.1 Research Methodology
    • 11.1.1 Methodology/Research Approach
      • 11.1.1.1 Research Programs/Design
      • 11.1.1.2 Market Size Estimation
      • 11.1.1.3 Market Breakdown and Data Triangulation
    • 11.1.2 Data Source
      • 11.1.2.1 Secondary Sources
      • 11.1.2.2 Primary Sources
  • 11.2 Author Details
  • 11.3 Disclaimer

List of Tables

  • Table 1. Insulin API Market Trends
  • Table 2. Insulin API Market Drivers & Opportunity
  • Table 3. Insulin API Market Challenges
  • Table 4. Insulin API Market Restraints
  • Table 5. Global Insulin API Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Insulin API Revenue Market Share by Company (2020-2025)
  • Table 7. Global Insulin API Sales Volume by Company (2020-2025) & (Tons)
  • Table 8. Global Insulin API Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Insulin API Price by Company (2020-2025) & (US$/kg)
  • Table 10. Key Manufacturers Insulin API Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Insulin API Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Insulin API
  • Table 13. Global Insulin API Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Insulin API as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Insulin API Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Insulin API Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Insulin API Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Insulin API Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Insulin API Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Insulin API Sales Volume by Type: 2020 VS 2024 VS 2031 (Tons)
  • Table 22. Global Insulin API Sales Volume by Type (2020-2025) & (Tons)
  • Table 23. Global Insulin API Sales Volume by Type (2026-2031) & (Tons)
  • Table 24. Global Insulin API Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Insulin API Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Insulin API Price by Type (2020-2025) & (US$/kg)
  • Table 27. Global Insulin API Price by Type (2026-2031) & (US$/kg)
  • Table 28. Global Insulin API Sales Value by Acting: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Insulin API Sales Value by Acting (2020-2025) & (US$ Million)
  • Table 30. Global Insulin API Sales Value by Acting (2026-2031) & (US$ Million)
  • Table 31. Global Insulin API Sales Market Share in Value by Acting (2020-2025)
  • Table 32. Global Insulin API Sales Market Share in Value by Acting (2026-2031)
  • Table 33. Global Insulin API Sales Volume by Acting: 2020 VS 2024 VS 2031 (Tons)
  • Table 34. Global Insulin API Sales Volume by Acting (2020-2025) & (Tons)
  • Table 35. Global Insulin API Sales Volume by Acting (2026-2031) & (Tons)
  • Table 36. Global Insulin API Sales Market Share in Volume by Acting (2020-2025)
  • Table 37. Global Insulin API Sales Market Share in Volume by Acting (2026-2031)
  • Table 38. Global Insulin API Price by Acting (2020-2025) & (US$/kg)
  • Table 39. Global Insulin API Price by Acting (2026-2031) & (US$/kg)
  • Table 40. Global Insulin API Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 41. Global Insulin API Sales Value by Application (2020-2025) & (US$ Million)
  • Table 42. Global Insulin API Sales Value by Application (2026-2031) & (US$ Million)
  • Table 43. Global Insulin API Sales Market Share in Value by Application (2020-2025)
  • Table 44. Global Insulin API Sales Market Share in Value by Application (2026-2031)
  • Table 45. Global Insulin API Sales Volume by Application: 2020 VS 2024 VS 2031 (Tons)
  • Table 46. Global Insulin API Sales Volume by Application (2020-2025) & (Tons)
  • Table 47. Global Insulin API Sales Volume by Application (2026-2031) & (Tons)
  • Table 48. Global Insulin API Sales Market Share in Volume by Application (2020-2025)
  • Table 49. Global Insulin API Sales Market Share in Volume by Application (2026-2031)
  • Table 50. Global Insulin API Price by Application (2020-2025) & (US$/kg)
  • Table 51. Global Insulin API Price by Application (2026-2031) & (US$/kg)
  • Table 52. Global Insulin API Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 53. Global Insulin API Sales Value by Region (2020-2025) & (US$ Million)
  • Table 54. Global Insulin API Sales Value by Region (2026-2031) & (US$ Million)
  • Table 55. Global Insulin API Sales Value by Region (2020-2025) & (%)
  • Table 56. Global Insulin API Sales Value by Region (2026-2031) & (%)
  • Table 57. Global Insulin API Sales Volume by Region (Tons): 2020 VS 2024 VS 2031
  • Table 58. Global Insulin API Sales Volume by Region (2020-2025) & (Tons)
  • Table 59. Global Insulin API Sales Volume by Region (2026-2031) & (Tons)
  • Table 60. Global Insulin API Sales Volume by Region (2020-2025) & (%)
  • Table 61. Global Insulin API Sales Volume by Region (2026-2031) & (%)
  • Table 62. Global Insulin API Average Price by Region (2020-2025) & (US$/kg)
  • Table 63. Global Insulin API Average Price by Region (2026-2031) & (US$/kg)
  • Table 64. Key Countries/Regions Insulin API Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 65. Key Countries/Regions Insulin API Sales Value, (2020-2025) & (US$ Million)
  • Table 66. Key Countries/Regions Insulin API Sales Value, (2026-2031) & (US$ Million)
  • Table 67. Key Countries/Regions Insulin API Sales Volume, (2020-2025) & (Tons)
  • Table 68. Key Countries/Regions Insulin API Sales Volume, (2026-2031) & (Tons)
  • Table 69. Novo Nordisk Company Information
  • Table 70. Novo Nordisk Introduction and Business Overview
  • Table 71. Novo Nordisk Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 72. Novo Nordisk Insulin API Product Offerings
  • Table 73. Novo Nordisk Recent Development
  • Table 74. Sanofi-Aventis Company Information
  • Table 75. Sanofi-Aventis Introduction and Business Overview
  • Table 76. Sanofi-Aventis Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 77. Sanofi-Aventis Insulin API Product Offerings
  • Table 78. Sanofi-Aventis Recent Development
  • Table 79. Eli Lilly Company Information
  • Table 80. Eli Lilly Introduction and Business Overview
  • Table 81. Eli Lilly Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 82. Eli Lilly Insulin API Product Offerings
  • Table 83. Eli Lilly Recent Development
  • Table 84. Tonghua Dongbao Company Information
  • Table 85. Tonghua Dongbao Introduction and Business Overview
  • Table 86. Tonghua Dongbao Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 87. Tonghua Dongbao Insulin API Product Offerings
  • Table 88. Tonghua Dongbao Recent Development
  • Table 89. Ganlee Company Information
  • Table 90. Ganlee Introduction and Business Overview
  • Table 91. Ganlee Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 92. Ganlee Insulin API Product Offerings
  • Table 93. Ganlee Recent Development
  • Table 94. United Laboratory Company Information
  • Table 95. United Laboratory Introduction and Business Overview
  • Table 96. United Laboratory Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 97. United Laboratory Insulin API Product Offerings
  • Table 98. United Laboratory Recent Development
  • Table 99. Biocon Company Information
  • Table 100. Biocon Introduction and Business Overview
  • Table 101. Biocon Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 102. Biocon Insulin API Product Offerings
  • Table 103. Biocon Recent Development
  • Table 104. Amphastar Company Information
  • Table 105. Amphastar Introduction and Business Overview
  • Table 106. Amphastar Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 107. Amphastar Insulin API Product Offerings
  • Table 108. Amphastar Recent Development
  • Table 109. Wockhardt Company Information
  • Table 110. Wockhardt Introduction and Business Overview
  • Table 111. Wockhardt Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 112. Wockhardt Insulin API Product Offerings
  • Table 113. Wockhardt Recent Development
  • Table 114. Julphar Diabetes Company Information
  • Table 115. Julphar Diabetes Introduction and Business Overview
  • Table 116. Julphar Diabetes Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 117. Julphar Diabetes Insulin API Product Offerings
  • Table 118. Julphar Diabetes Recent Development
  • Table 119. Torrent Pharma Company Information
  • Table 120. Torrent Pharma Introduction and Business Overview
  • Table 121. Torrent Pharma Insulin API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 122. Torrent Pharma Insulin API Product Offerings
  • Table 123. Torrent Pharma Recent Development
  • Table 124. Key Raw Materials Lists
  • Table 125. Raw Materials Key Suppliers Lists
  • Table 126. Insulin API Downstream Customers
  • Table 127. Insulin API Distributors List
  • Table 128. Research Programs/Design for This Report
  • Table 129. Key Data Information from Secondary Sources
  • Table 130. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Insulin API Product Picture
  • Figure 2. Global Insulin API Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Insulin API Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Insulin API Sales Volume (2020-2031) & (Tons)
  • Figure 5. Global Insulin API Sales Price (2020-2031) & (US$/kg)
  • Figure 6. Insulin API Report Years Considered
  • Figure 7. Global Insulin API Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Insulin API Players Sales Volume Ranking (2024) & (Tons)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Insulin API Revenue in 2024
  • Figure 10. Insulin API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Regular Human Insulin Picture
  • Figure 12. Insulin Analogue Picture
  • Figure 13. Global Insulin API Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Insulin API Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Insulin API Sales Volume by Type (2020 VS 2024 VS 2031) & (Tons)
  • Figure 16. Global Insulin API Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Insulin API Price by Type (2020-2031) & (US$/kg)
  • Figure 18. Rapid-acting Picture
  • Figure 19. Short-acting Picture
  • Figure 20. Intermediate-acting Picture
  • Figure 21. Long-acting Picture
  • Figure 22. Ultra-long-acting Picture
  • Figure 23. Global Insulin API Sales Value by Acting (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 24. Global Insulin API Sales Value Market Share by Acting, 2024 & 2031
  • Figure 25. Global Insulin API Sales Volume by Acting (2020 VS 2024 VS 2031) & (Tons)
  • Figure 26. Global Insulin API Sales Volume Market Share by Acting, 2024 & 2031
  • Figure 27. Global Insulin API Price by Acting (2020-2031) & (US$/kg)
  • Figure 28. Product Picture of Preparation Production
  • Figure 29. Product Picture of Biosimilar Drug Development
  • Figure 30. Product Picture of Scientific Research
  • Figure 31. Product Picture of Other
  • Figure 32. Global Insulin API Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 33. Global Insulin API Sales Value Market Share by Application, 2024 & 2031
  • Figure 34. Global Insulin API Sales Volume by Application (2020 VS 2024 VS 2031) & (Tons)
  • Figure 35. Global Insulin API Sales Volume Market Share by Application, 2024 & 2031
  • Figure 36. Global Insulin API Price by Application (2020-2031) & (US$/kg)
  • Figure 37. North America Insulin API Sales Value (2020-2031) & (US$ Million)
  • Figure 38. North America Insulin API Sales Value by Country (%), 2024 VS 2031
  • Figure 39. Europe Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Europe Insulin API Sales Value by Country (%), 2024 VS 2031
  • Figure 41. Asia Pacific Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Asia Pacific Insulin API Sales Value by Region (%), 2024 VS 2031
  • Figure 43. South America Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. South America Insulin API Sales Value by Country (%), 2024 VS 2031
  • Figure 45. Middle East & Africa Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Middle East & Africa Insulin API Sales Value by Country (%), 2024 VS 2031
  • Figure 47. Key Countries/Regions Insulin API Sales Value (%), (2020-2031)
  • Figure 48. Key Countries/Regions Insulin API Sales Volume (%), (2020-2031)
  • Figure 49. United States Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. United States Insulin API Sales Value by Type (%), 2024 VS 2031
  • Figure 51. United States Insulin API Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Europe Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. Europe Insulin API Sales Value by Type (%), 2024 VS 2031
  • Figure 54. Europe Insulin API Sales Value by Application (%), 2024 VS 2031
  • Figure 55. China Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 56. China Insulin API Sales Value by Type (%), 2024 VS 2031
  • Figure 57. China Insulin API Sales Value by Application (%), 2024 VS 2031
  • Figure 58. Japan Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 59. Japan Insulin API Sales Value by Type (%), 2024 VS 2031
  • Figure 60. Japan Insulin API Sales Value by Application (%), 2024 VS 2031
  • Figure 61. South Korea Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 62. South Korea Insulin API Sales Value by Type (%), 2024 VS 2031
  • Figure 63. South Korea Insulin API Sales Value by Application (%), 2024 VS 2031
  • Figure 64. Southeast Asia Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 65. Southeast Asia Insulin API Sales Value by Type (%), 2024 VS 2031
  • Figure 66. Southeast Asia Insulin API Sales Value by Application (%), 2024 VS 2031
  • Figure 67. India Insulin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 68. India Insulin API Sales Value by Type (%), 2024 VS 2031
  • Figure 69. India Insulin API Sales Value by Application (%), 2024 VS 2031
  • Figure 70. Insulin API Industrial Chain
  • Figure 71. Insulin API Manufacturing Cost Structure
  • Figure 72. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 73. Bottom-up and Top-down Approaches for This Report
  • Figure 74. Data Triangulation
  • Figure 75. Key Executives Interviewed